OncoCyte Retained Earnings (Accumulated Deficit) 2014-2025 | IMDX
OncoCyte retained earnings (accumulated deficit) from 2014 to 2025. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
OncoCyte Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024 |
$-351 |
| 2023 |
$-290 |
| 2022 |
$-261 |
| 2021 |
$-188 |
| 2020 |
$-124 |
| 2019 |
$-94 |
| 2018 |
$-71 |
| 2017 |
$-55 |
| 2016 |
$-35 |
| 2015 |
$-24 |
| 2014 |
$-15 |
| 2013 |
$-10 |
OncoCyte Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2025-03-31 |
$-357 |
| 2024-12-31 |
$-351 |
| 2024-09-30 |
$-317 |
| 2024-06-30 |
$-304 |
| 2024-03-31 |
$-299 |
| 2023-12-31 |
$-290 |
| 2023-09-30 |
$-272 |
| 2023-06-30 |
$-266 |
| 2023-03-31 |
$-258 |
| 2022-12-31 |
$-261 |
| 2022-09-30 |
$-216 |
| 2022-06-30 |
$-206 |
| 2022-03-31 |
$-198 |
| 2021-12-31 |
$-188 |
| 2021-09-30 |
$-152 |
| 2021-06-30 |
$-138 |
| 2021-03-31 |
$-128 |
| 2020-12-31 |
$-124 |
| 2020-09-30 |
$-117 |
| 2020-06-30 |
$-111 |
| 2020-03-31 |
$-101 |
| 2019-12-31 |
$-94 |
| 2019-09-30 |
$-86 |
| 2019-06-30 |
$-81 |
| 2019-03-31 |
$-75 |
| 2018-12-31 |
$-71 |
| 2018-09-30 |
$-67 |
| 2018-06-30 |
$-64 |
| 2018-03-31 |
$-59 |
| 2017-12-31 |
$-55 |
| 2017-09-30 |
$-51 |
| 2017-06-30 |
$-44 |
| 2017-03-31 |
$-40 |
| 2016-12-31 |
$-35 |
| 2016-09-30 |
$-32 |
| 2016-06-30 |
$-30 |
| 2016-03-31 |
$-27 |
| 2015-12-31 |
$-24 |
| 2015-09-30 |
|
| 2015-06-30 |
|
| 2015-03-31 |
|
| 2014-12-31 |
$-15 |
| 2013-12-31 |
$-10 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Services |
$0.090B |
$0.002B |
|
OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California.
|
